Cell and Gene Therapy Model Access Model to Expand Beyond Sickle Cell Disease Treatments Following Positive Results in First Evaluation Repo
October 27, 2026 | |
Cell and Gene Therapy Model Access Model to Expand Beyond Sickle Cell Disease Treatments Following Positive Results in First Evaluation Repo
The Center for Medicare and Medicaid Innovation announced that it intends on expanding the Cell and Gene Therapy (CGT) Access Model scope beyond sickle cell disease (SCD) treatments, following the positive results from the first model evaluation report. What this means. In the coming months, CMMI will release a request for applications (RFA) and invite manufacturers of other cell and… (Slifer, October 27, 2026) #Demonstration Programs, #Medicaid, #Prescription Drugs
